It has been initially reported that 4-tertiary butyl phenol (4-TBP)-treated vitiligo PIG3V melanocytes may mediate the activation of disease-effector dendritic cells (DCs) through the release of Hsp70 [84]. The gene discussed is HSPA1A; the disease is vitiligo.